Table 2.
MAC | –9 | –8 | –7 | –6 | –5 | –4 | –3 | –2 | –1 | 0 |
---|---|---|---|---|---|---|---|---|---|---|
TBI-based regimen | ||||||||||
TBI 9.9–12 Gy | ↓ | ↓ | ↓ | |||||||
fludarabine 30 mg/m2/day | ↓ | ↓ | ↓ | ↓ | ||||||
Non-TBI regimen | ||||||||||
fludarabine 30 mg/m2/day | ↓ | ↓ | ↓ | ↓ | ||||||
melphalan 90 mg/m2/day | ↓ | ↓ | ||||||||
fludarabine 30 mg/m2/day | ↓ | ↓ | ↓ | ↓ | ||||||
targeted busulfan (total AUC 80–100 mg × h/L) |
↓ | ↓ | ↓ | ↓ | ||||||
RIC | ||||||||||
fludarabine 30 mg/m2/day | ↓ | ↓ | ↓ | ↓ | ||||||
melphalan 70 mg/m2/day | ↓ | ↓ | ↓ | |||||||
fludarabine 30 mg/m2/day | ↓ | ↓ | ↓ | ↓ | ↓ | |||||
cyclophosphamide 14.5 mg/kg/day |
↓ | ↓ | ||||||||
TBI 2 Gy | ↓ |
MAC, myeloablative conditioning; TBI, total body irradiation; AUC, area under the concentration-time curve; RIC, reduced intensity conditioning; ↓, date of administration or irradiation.